Syncromune, Inc.
Filings
| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-115/11/26 | Amended | $144,828,791 | $32,999,998 | Equity Only | 06b | SEC linkSEC |
| 2025-08-218/21/25 | Amended | $111,828,793 | $0 | Equity Only | SEC linkSEC | |
| 2024-12-1712/17/24 | New | $50,828,889 | $50,828,889 | Equity Only | 06b | SEC linkSEC |
| 2023-10-0610/6/23 | Amended | $14,180,000 | $8,870,000 | Equity Only | 06b | SEC linkSEC |
| 2022-11-2911/29/22 | New | $5,310,000 | $5,310,000 | Equity Only | 06c | SEC linkSEC |
Directors and Executives (Current and Past)
| Name | Role |
|---|---|
| Gregory J. Champion | Executive |
| Jeffrey L. Cleland | Director |
| Stephen Dale | Executive |
| Agustin Gago | Executive |
| Joseph Gerardi | Executive |
| Eamonn Hobbs | Director, Executive |
| Jeffrey Kraws | Executive |
| Charles J. Link | Director, Executive |
| Joseph C. Maroon | Director |
| Kerri Ann Millar | Executive |
| Norman Schwartz | Director |
| Douglas G. Watson | Director |
Industry: Biotechnology (See others in industry)
Address:
2919 E. Commercial Blvd., Suite 200
Fort Lauderdale, FL, 33308
Phone: 518-796-6110
Fort Lauderdale, FL, 33308
Phone: 518-796-6110